Inclusion Criteria:  Initial diagnosis of histologically confirmed locally advanced and/or metastatic carcinoma Radiologically confirmed progression under the most recent therapy No further evidence-based drug treatment is established, or no satisfactory alternative treatments are available for the locally advanced and/or metastasized carcinoma Further therapy is medically feasible ECOG (Eastern Cooperative Oncology Group) performance status 0-2 Life expectancy of at least 12 weeks Written informed consent and willingness to cooperate during the course of the study Capability to understand the intention and the consequences of the study  Exclusion Criteria:  Untreated CNS (central nervous system) metastases. Patients with treated CNS metastases are eligible if they are clinically stable with regard to neurologic function Pregnant or breast feeding Other malignomas, diagnosed < 5a before inclusion (except localized squamous cell carcinomas of the skin, surgically curable melanomas of the skin, basal cell carcinomas of the skin)